SLE Therapy Changes in Pregnancy & Relation to Pregnancy Outcome

Status Completed

Clinical Trial Summary

to review the changes to SLE medications during pregnancy including adherence and non-adherence to the medications and correlate these to the pregnancy outcome and post-partum course of the disease.

Clinical Trial Description

This was a retrospective study of pregnancies in SLE patients. These patients had confirmed SLE diagnosis according to the American College of Rheumatology (ACR) criteria (5). The diagnosis of SLE was confirmed by consultant rheumatologist. These patients were followed up by consultant rheumatologist and obstetrician. The pregnancies' data were curated using the patients' medical files and notes, both paper-based and electronic, antenatal records, rheumatology and hematology clinic notes in addition to delivery and postpartum records. These data were collected including ID numbers, ages, duration of the SLE, their SLE medications before the pregnancy (names, doses and frequency) and whether the SLE was active or not in the 6 months prior to the pregnancy using systemic lupus erythematosus disease activity index (SLEDAI) score. the investigators studied Hydroxychloroquine (HCQ), prednisolone and anti-coagulants (low-dose acetylsalicylic acid; 100 mg orally once daily and low molecular weight heparins (LMWH) Enoxaparin 40 mg subcutaneously once daily) as these were the most commonly used medications. The use of these medications in the different pregnancy periods were noted and analyzed (BPG, before pregnancy; DPG, during pregnancy; PG, pregnancy; PP, post-partum). Changes in these medications were also recorded. The data was then analyzed to find out the rates of changes and discontinuation. The postpartum period was also studied similarly. The investigators correlated these alterations to the following feto-maternal outcomes; miscarriage, preterm delivery, intra-uterine growth restriction (IUGR) and intra-uterine fetal death (IUFD). The 6 months-pre-conceptual SLEDAI score was recorded and investigated in relation to the above mentioned feto-maternal outcomes and postpartum relapse. We divided the pregnancies into 2 groups; Group A, inactive SLE and SLEDAI score of 0-3; Group b, active SLE and SLEDAI score of 4-24. ;

Study Design

Related Conditions & MeSH terms

Fetal Growth Retardation

Clinical Trial Details

NCT number	NCT05176041
Study type	Observational
Source	University of Jordan
Contact
Status	Completed
Phase
Start date	September 2016
Completion date	January 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05899101` - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed	`NCT04502823` - Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler	N/A
Not yet recruiting	`NCT03625518` - Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes	Early Phase 1
Completed	`NCT02379728` - Ghana PrenaBelt Trial: A Positional Therapy Device to Reduce Still-Birth	N/A
Completed	`NCT01695070` - Melatonin to Prevent Brain Injury in Unborn Growth Restricted Babies	Phase 4
Completed	`NCT01352234` - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia	Phase 4
Completed	`NCT04289350` - Day to Day Variation in Fetal Heart Rate Variability
Recruiting	`NCT03662178` - Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Recruiting	`NCT05023161` - Non-invasive Placental Chromosome Exploration of Intrauterine Growth Restriction
Completed	`NCT02590536` - A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction	Phase 3
Not yet recruiting	`NCT05029778` - Arginine + Citrulline as a Supplement for Weight Gain in Fetus With a Decrease in Their Growth Curve	Phase 4
Recruiting	`NCT05576207` - BEP Supplementation Research in Bangladesh (JiVitA-BEP-IR)	N/A
Active, not recruiting	`NCT05160649` - Effect of Covid 19 Infection on Fetomaternal Outcome
Completed	`NCT02280031` - Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial.	Phase 2
Recruiting	`NCT04389099` - MRI Angiography of Physiological and Pathological Pregnancy Placentas Ex-vivo
Recruiting	`NCT06039319` - Acute Effects of Maternal Exercise and the Growth Restricted Pregnancy
Recruiting	`NCT05651347` - Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction	Phase 3
Recruiting	`NCT02336243` - A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders	Phase 3
Active, not recruiting	`NCT01594463` - Routine Ultrasound Screening in the Third Trimester	N/A
Completed	`NCT00465634` - Doppler and Biological Second Trimester Placental Insufficiency Screening	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

SLE Therapy Changes in Pregnancy and Relation to Pregnancy Outcome

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms